Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

NCT06778408

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Vermont Medical Center
Enrollment	103 participants

Key Eligibility Criteria

Inclusion (12)

- Histological confirmation of cancer with radiographic (CT, MRI or PET) evidence of metastatic disease
- Palliative radiotherapy indicated for bone or soft tissue metastases, or primary targets, located in the thorax, abdomen, or pelvis as part of their standard of care treatment plan
- Age e 18 years.
- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- In lieu of a pregnancy test, participants may sign the Pregnancy Attestation Form, a standard form routinely used in clinical practice at UVMCC.

... and 7 more (see full listing online)

Exclusion (3)

- Patients receiving any other investigational agents or concurrent cytotoxic chemotherapy
- Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
- Serious medical comorbidities, which in the opinion of the radiation oncologist preclude the delivery of RT

Locations (1 total)

University of Vermont Medical Center, Burlington, Vermont, United States